Contrasting FluoroPharma Medical (OTCMKTS:FPMI) & biote (NASDAQ:BTMD)

FluoroPharma Medical (OTCMKTS:FPMI) and biote (NASDAQ:BTMD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Volatility and Risk

FluoroPharma Medical has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, biote has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for FluoroPharma Medical and biote, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FluoroPharma Medical	0	0	0	0	0.00
biote	1	1	1	1	2.50

biote has a consensus price target of $2.75, indicating a potential upside of 21.68%. Given biote’s stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than FluoroPharma Medical.

Institutional & Insider Ownership

21.7% of biote shares are owned by institutional investors. 36.9% of FluoroPharma Medical shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares FluoroPharma Medical and biote”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FluoroPharma Medical	N/A	N/A	N/A	N/A	N/A
biote	$192.22 million	0.44	$27.05 million	$0.44	5.14

biote has higher revenue and earnings than FluoroPharma Medical.

Profitability

This table compares FluoroPharma Medical and biote’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
FluoroPharma Medical	N/A	N/A	N/A
biote	8.29%	-25.72%	15.12%

Summary

biote beats FluoroPharma Medical on 9 of the 11 factors compared between the two stocks.

About FluoroPharma Medical

FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.